Marisa Wexler, MS,  senior science writer—

Soliris (eculizumab) is safe and effective for the prevention of recurrence in people with atypical hemolytic uremic syndrome (aHUS) who received kidney transplants, a 10-year follow-up study indicates. The study, “Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome–…

Atypical hemolytic uremic syndrome (aHUS) can co-exist with autoimmune disorders, complicating the diagnosis of the rare blood-clotting disease, a case report shows. The findings highlight the need for genetic testing to diagnose aHUS in complex cases, the researchers said. The case report, “Atypical Hemolytic…

A rare type of inflammatory arthritis known as Still’s disease may trigger the development of atypical hemolytic uremic syndrome (aHUS), a recent case report suggests. A timely diagnosis of these conditions is critical to avoid irreparable damage to organs, the authors warn. The report, “Aggressive…

Atypical hemolytic uremic syndrome (aHUS) can co-exist with autoimmune thyroid disease, and the two conditions may influence each other’s development, a case report suggests. The report, “Atypical hemolytic uremic syndrome precipitated by thyrotoxicosis: a case report,” was published in BMC Pediatrics. Autoimmune thyroid disease (AITD)…

The first known case of atypical hemolytic uremic syndrome (aHUS) and adult-onset cobalamin C deficiency, a metabolic disorder, occurring together in the same person was described in a recent case report. The report, “Cobalamin c deficiency associated with antifactor h antibody-associated hemolytic uremic syndrome in…

The Committee for Medicinal Products for Human Use (CHMP), a branch of the European Medicines Agency (EMA), is recommending that Alexion Pharmaceuticals‘ Ultomiris (ravulizumab-cwvz) be approved to treat children and adults with atypical hemolytic uremic syndrome (aHUS). A final decision from the European Commission is expected in the…

Scientists have discovered, in a Chinese patient, new mutations in the DGKE gene that can cause atypical hemolytic uremic syndrome (aHUS), a case report shows. These new mutations expand current knowledge of this gene in the context of aHUS, and highlight potential racial differences in DGKE genetic…

Treatment with Soliris (eculizumab) led to successful resolution of atypical hemolytic uremic syndrome (aHUS) that was triggered by inflammatory bowel disease (IBD), a study of two cases has found. The study, “Successful use of eculizumab to treat atypical hemolytic uremic syndrome in patients with inflammatory bowel…